+972-77-2005042 8 am to 11 pm (Illinois)

+972-77-2005042 8 am to 11 pm (Illinois)

Tel Aviv, Israel, April 21, 2021/PRNewswire/ - Nasus Pharma, a private clinical-stage biopharmaceutical company, develops a powder-based intranasal (PBI) product portfolio to respond to acute medical conditions and public health threats, announced today An in vitro study conducted in collaboration with the Central Virology Laboratory of the Israeli Ministry of Health, the Ministry of Public Health Services, and the Central Virology Laboratory of Tel Hashomer in Ramat Gan, Israel, showed that Taffix® powder produced after the administration of tissue culture infectious doses Gel layer The virus effectively prevented 100% of the two new highly infectious variants of the SARS-CoV-2 virus (the "UK" and "South Africa" ​​variants), as it did on the Tafix-incubated cells inoculated with the virus As proved by the qt PCR test.

"These important results are consistent with previous in vitro studies conducted with Taffix, in which 99.99% of the SARS-CoV-2 virus was blocked by Taffix[1] and other viruses known to cause upper respiratory tract infections. Importantly, these results are consistent with The real situation is consistent with Taffix’s clinical experience in life. After the “super spreader” event, the risk of contracting COVID has been reduced by 78%. [2] These consistent results on multiple strains prove the power against the spread of multiple respiratory viruses Non-specific activity," said Dr. Dalia Megiddo, CEO of Nasus Pharma. "The results of this study once again confirm the versatility of our technology against various respiratory viruses, including SARS-CoV-2 and its new variants, as well as the potential of Taffix as an important additional layer of infection protection.

Udi Gilboa, Chairman of Nasus Pharma’s Board of Directors, added: “There is an urgent need for solutions that can safely resume economic and social activities. The dynamic changes of the virus and the continued emergence of other mutations pose challenges to public health. Our new data shows that in addition to all other recommendations In addition to the security measures, Taffix can also help prevent the spread of these new variants. With the increasing use of Taffix around the world, we understand that additional layers of protection are useful in promoting a return to normalcy."

Taffix® is currently sold in more than 20 countries/regions in Europe, Latin America, Asia and the Middle East. It is designed to create an acidic microenvironment in the nose and has been proven to prevent viruses from entering and infecting nasal cells. It has now been determined that the nose is the main route of airborne droplet virus infection (including SARS-COV-2). Taffix® powder forms a unique thin acidified gel above the nasal mucosa for 5 hours, which significantly protects nasal cells from inhaled viruses through mechanical and chemical protection. Therefore, in addition to the various preventive measures taken today to prevent the further spread of the new SARS-COV-2 variant, Taffix® may be an important new protection tool.   

Based on its unique microsphere technology, Nasus Pharma is developing a variety of intranasal powder products designed to help patients cope with a variety of acute emergencies, such as opioid overdose and anaphylactic shock.

Intranasal administration is most suitable for occasions that require rapid administration, and has multiple advantages such as rapid administration, convenient use, non-invasive, and safety. Nasus' product portfolio includes multiple projects: intranasal naloxone (key research completed) and intranasal adrenaline (phase 2 completed), as well as many preclinical POC projects.

[1] Man, Barbara J., et al. "Taffix® nasal powder forms an effective barrier to SARS-CoV-2." Journal of Biomedical Science and Technology Research 33.3 (2021): 25843-25845.

[2] Klang Shmuel, Megiddo Dalia, Lapidot Tair and Naparstek Yaakov (2021). Low pH hypromellose (Taffix) nasal spray can reduce the SARS-CoV-2 infection rate after a large-scale clustering event in a highly prevalent community: an observational prospective open-label user survey, comments from anti-infective treatment experts, DOI: 10.1080/14787210.2021 .1908127

Contact: [Email Protection] www.Tafixprotect.com

More news releases on similar topics

+972-77-2005042 8 am to 11 pm (Illinois)